Umbiko Wecala Lokuphendula Okuphelele Kwesikhathi Eside ku-Hepatocellular Carcinoma kuma-GPC3 CAR T Cells (CT011)

I-CT011 iwumkhiqizo we-GPC3 CAR T-cell ozimele ofanele ukwelashwa kwe-hepatocellular carcinoma (HCC). I-CT011 yathola imvume ye-IND evela kwi-NMPA ngo-2019 yokwelapha iziguli ezine-GPC3-positive solid tumor okwakuyimvume yokuqala ye-IND eShayina yokwelashwa kwe-CAR T-cell ngokumelene nezimila eziqinile.

Mhla ziyi-18 kuNcwaba, 2022, i-CARsgen Therapeutics imemezela ukuthi umbiko wecala, onesihloko esithi “Impendulo Ephelele Yesikhathi Eside Ye-Advanced Hepatocellular Carcinoma ku-Glypican-3 Specific Chimeric Antigen Receptor T-Cells kanye ne-Sorafenib, Umbiko wecala”, ushicilelwe ku-Frontiers in Immunology.

Icala libonise isiguli sesilisa sase-Asia esineminyaka engu-60 ubudala esine-HCC ehlobene ne-hepatitis B virus (HBV) esahlinzwa ngoMeyi 2018. Ngo-Agasti 2018, ukuphinda kuvele umdlavuza wesibindi kanye nokusabalala kwamaphaphu kwenzeka ngemuva kokuhlinzwa, wabe esethola i-transarterial chemoembolization (TACE) yokwelapha izilonda zesibindi kanye nokususwa kwezicubu ukuze kwelashwe ukusabalala kwamaphaphu. Ezinyangeni ezimbili kamuva, wathuthuka futhi wabhaliswa esivivinyweni somtholampilo. Ngemva kokubhaliswa, isiguli senziwa i-leukapheresis yokukhiqiza amaseli e-CAR-GPC3 T. Ezinsukwini eziyisikhombisa ngemva kwe-leukapheresis, isiguli saqala ukuthola ama-400 mg we-sorafenib kabili ngosuku. Isiguli sathola imijikelezo emi-4 yokwelashwa kwamaseli e-CAR-GPC3 T (CT011) futhi umjikelezo ngamunye wahlukaniswa waba ama-infusions amabili. Ngaphambi komjikelezo ngamunye wokwelashwa kwe-CT011, kwenziwa i-lymphodepletion. Isamba esingu-4×10⁹Amaseli e-T e-CAR-GPC3 afakwe.

Ukwelashwa okuhlanganisiwe kwe-CT011 kanye ne-sorafenib kwabekezelelwa kahle. Lesi siguli sathola izimpendulo ezingaphelele (PR) kusukela ngenyanga yesi-3 futhi sathola i-CR ngenyanga ye-12 ngemuva komjikelezo wokuqala wokufakwa kwe-CT011. Isimila asizange siqhubeke isikhathi esingaphezu kwezinyanga ezingama-36 futhi sagcina isimo se-CR isikhathi esingaphezu kwezinyanga ezingama-24 ngemuva kokufakwa kokuqala.

Ngokwazi kwethu, lesi yisimo sokuqala esibikiwe nge-CR ngemuva kokwelashwa okuhlanganisiwe kwamaseli e-CAR T nama-inhibitor e-tyrosine kinase. Umphumela wezokwelapha ukhombisile ukuthi ukwelashwa okuhlanganisiwe kwe-GPC3 CAR T-cell kanye ne-Sorafenib kungaba yindlela entsha ethembisayo yeziguli ze-GPC3+ ezithuthukile ze-HCC.

Njengamanje, kunezinye izivivinyo eziningi ze-CAR-T eShayina, futhi zifuna iziguli. Ukuze uthole ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.

Inombolo yocingo: 4008803716

Email：myimmnet@163.com